Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Moderna Inc
(NQ:
MRNA
)
86.84
+0.22 (+0.25%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Moderna Inc
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Novavax Stock’s Recent Surge and Future Potential
June 06, 2024
Novavax's future hinges on its ability to translate recent stock market momentum into sustained financial performance.
Via
MarketBeat
Topics
Economy
Exposures
COVID-19
Product Safety
Supply Chain
FDA Selects Moderna's Rare Disease Candidate For Accelerated Development Program
June 06, 2024
Moderna's mRNA-370 has been selected for the FDA's START program to accelerate rare disease therapeutics, targeting a 2024 pivotal study.
Via
Benzinga
Exposures
Product Safety
Is a Giant Short Squeeze Brewing in Novavax (NVAX) Stock?
June 06, 2024
Novavax will be ready for the new Covid-19 JN.1 variants in September, but NVAX stock is also undergoing a short squeeze.
Via
InvestorPlace
Exposures
COVID-19
Novavax, With A 369% Gain, Tears Ahead Again On Key FDA Move
June 06, 2024
Novavax also said it's planning to launch a JN.1-focused Covid booster shot this fall.
Via
Investor's Business Daily
Exposures
COVID-19
Product Safety
Dyadic International Inc. (NASDAQ: DYAI) Hits New 52-Week High Amidst Golden Cross, Bullish Swing Patterns and Bird Flu Concerns
June 06, 2024
Via
AB Newswire
If You Invested $100 In This Stock 5 Years Ago, You Would Have $800 Today
June 03, 2024
Via
Benzinga
Breaking Down Moderna: 7 Analysts Share Their Views
June 03, 2024
Via
Benzinga
Moderna's Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program
June 06, 2024
Via
ACCESSWIRE
Biotech Blockbusters: 3 Pharma Stocks to Buy in June for Breakthrough Potential
June 05, 2024
If you have the patience and the ability to take a little risk, consider these three biotech stocks to buy since they can really pay off.
Via
InvestorPlace
Why Is Novavax (NVAX) Stock Up 20% Today?
June 05, 2024
Novavax continues to march higher in its recovery efforts, with its latest vaccine announcement lifting NVAX stock.
Via
InvestorPlace
S&P 500, Nasdaq 100 Jointly Hit All-Time Highs, Nvidia Overtakes Apple As Second Most Valuable US Company
June 05, 2024
The S&P 500 and Nasdaq 100 indices closed at record highs due to investor confidence in AI-driven tech sector growth. Magnificent Seven worth $15T.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
May 31, 2024
Via
ACCESSWIRE
Why Moderna Stock Is Sinking This Week
May 30, 2024
Moderna's sell-off this week is for the birds.
Via
The Motley Fool
What's Going On With Novavax Stock?
June 05, 2024
Novavax, Inc. shares are trading higher Wednesday, and the stock is up by more than 300% over the past month. Here's a look at what's going on.
Via
Benzinga
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
June 04, 2024
On Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial. On Monday, Moderna (NASDAQ: MRNA) and Merck & Co...
Via
Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
June 04, 2024
https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate
Via
InvestorPlace
Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
June 03, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients
June 03, 2024
Moderna and Merck's Phase 2b study results for mRNA-4157 combined with Keytruda, showing improvements in recurrence-free and distant metastasis-free survival for high-risk melanoma patients. Phase 3...
Via
Benzinga
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage
June 03, 2024
Via
ACCESSWIRE
Is Moderna Stock a Buy Now That It's a 2-Product Company?
June 03, 2024
The Food and Drug Administration recently approved a new vaccine from Moderna, but the stock dipped in response.
Via
The Motley Fool
Moderna Investors Just Got Some Bullish News
June 03, 2024
This news could be worth billions...
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
May 31, 2024
Via
Benzinga
Moderna Scores FDA Approval For Its Second Product - Respiratory Syncytial Virus Vaccine
May 31, 2024
FDA approves Moderna's mRESVIA (mRNA-1345), an mRNA vaccine for RSV, for adults 60+. The second approved mRNA product from Moderna.
Via
Benzinga
Exposures
Product Safety
Moderna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK
May 31, 2024
Moderna's RSV vaccine will launch a year behind Pfizer and GSK, but it could become the market leader over the next five years.
Via
Investor's Business Daily
Exposures
Product Safety
3 Sorry Biotech Stocks to Sell in May While You Still Can
May 31, 2024
Morgan Stanley's bullish outlook highlights the need for strategic trimming of underperforming biotech stocks to sell.
Via
InvestorPlace
Dyadic International Inc. (DYAI): Bird Flu Vaccine Development Amid Rising Pandemic Concerns
May 30, 2024
Via
AB Newswire
Exposures
COVID-19
Moderna Pops After Confirming The U.S. Government Could Back Its Bird Flu Vaccine
May 30, 2024
The company expects to have data soon from its Phase 1 and Phase 2 study of a bird flu vaccine.
Via
Investor's Business Daily
3 Nasdaq Stocks to Dump as They Near Peak Performance
May 30, 2024
Moderna, Constellation Energy and CrowdStrike are three Nasdaq stocks to sell, each offering unique exit points in a peaking market.
Via
InvestorPlace
Cathie Wood-LedArk Invest Cuts Robinhood Holdings Amid Bitcoin Dip, Keeps Selling Moderna Stock — Buys Palantir And AMD Shares
May 29, 2024
On Wednesday, Ark Invest, led by the influential investor Cathie Wood, executed notable trades involving Robinhood Markets Inc (NASDAQ:HOOD), Moderna Inc (NASDAQ:MRNA), Palantir
Via
Benzinga
VIX Rises 8%, Treasury Yields Jump, Dow Plunges: Why Is Wall Street Wobbling Thursday?
May 29, 2024
Wall Street opens with red showing as investors worry about interest rates. Volatility and Treasury yields spike. Traders expect 1-2 rate cuts.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.